Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | FABP4 | P15090 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4629046 | 0.90 | CA1 (0.49) | MAPK1FABP4CA1CA2CYP1A2 | |
| SCHEMBL4626825 | 0.84 | POLB (0.46) | MAPK1KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL9771650 | 0.82 | MAPK1 (0.67) | MAPK1FABP4CA1CA2CYP1A2 | |
| SCHEMBL4628943 | 0.81 | NPC1 (0.68) | CYP1A2CYP2C9CYP2C19KDM4EALDH1A1 | |
| SCHEMBL4626771 | 0.80 | KDM4E (0.51) | MAPK1CA1CA2KDM4EALDH1A1 | |
| SCHEMBL2956135 | 0.80 | HPGD (0.47) | CA1CA2KDM4EALDH1A1HPGD | |
| SCHEMBL9717451 | 0.79 | MAPK1 (0.85) | MAPK1FABP4CA1CA2CYP1A2 | |
| SCHEMBL4627897 | 0.79 | L3MBTL1 (0.49) | KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL4626883 | 0.77 | HDAC2 (0.59) | — | |
| SCHEMBL2033165 | 0.76 | MAPK1 (0.73) | MAPK1FABP4CA1CA2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129264-B2 | Biarylmethyl indolines and indoles as antithromboembolic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-31 | — | — | US | claimed |
| US-20040220206-A1 | Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-04 | — | — | US | claimed |
| EP-1633716-A4 | BIARYLMETHYL INDOLINES, INDOLES AND TETRAHYDROQUINOLINES, USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-26 | — | — | EP | disclosed |
| US-7129264-B2 | Biarylmethyl indolines and indoles as antithromboembolic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1633716-A2 | BIARYLMETHYL INDOLINES, INDOLES AND TETRAHYDROQUINOLINES, USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004094372-A2 | COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040220206-A1 | Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220206-A1 | Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors | TFPI, TFPI2, F2 | MAPK1 1438/4885FABP4 4476/4885CA1 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.